People
Some have wondered why the agency has hit back at Novartis so hard when the data in question didn’t have any effect on the eventual outcomes of the product’s effectiveness and safety.
Scot Ebbinghaus, Vice President and Therapeutic Area Head, Oncology Clinical Research, Merck Research Laboratories, took time out ahead of the meeting to discuss three of the company’s clinical trials being presented and the implications for oncology patients and Merck.
Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.
“It’s important to recognize that this problem is there and this problem is persisting over the years,” Kanwal Raghav, author of the study and an oncologist at MD Anderson Cancer Center, told STAT.
The data-manipulation scandal with Novartis is widening, undermining investors’ trust in company chief executive officer Vas Narasimhan.
When it comes to potential pricing controls of the pharmaceutical industry, Jim Greenwood, chief executive officer of BIO, grimly stated that “nothing good” was going on in the halls of power in Washington, D.C.
Jill Adler-Moore, a renowned microbiologist and professor emerita at Cal Poly Pomona, was honored for her research, leadership and years of mentorship during a Cal State LA BioSpace event celebrating emerging entrepreneurs.
Biopharma companies strengthen their executive ranks and boards with new additions.
According to a regulatory filing, Saunders will walk away with $14.9 million in cash and $23.6 million in equity, mostly stock based on performance.
In a brief announcement, AveXis said the Kaspar brothers have not been involved in any operations at AveXis since early May, seemingly ahead of the U.S. Food and Drug Administration’s approval of Zolgensma.
PRESS RELEASES